ConductScience.org, home

Trial · NCT01116583

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPersistent post surgical pain3 months after surgery
Pain is assessed by means of the Brief Pain Inventory (BPI-SF) and The McGill Pain Questionnaire (SF-MPQ). Persistent postoperative pain is measured both on a 11-point numeric pain rating scale and on a 10 cm visual analog scale (VAS). A score \>=3 is considered as moderate pain.
PrimaryAcute postoperative painWithin the first 5 postoperative days
Acute postoperative pain is measured on a 11-point numeric rating scale both at rest and when coughing/sitting up. General pain intensity and specific (shoulder) pain intensity are measured. On postoperative day 4 pain is furthermore assessed by means of the Brief Pain Inventory (BPI-SF) and The McGill Pain Questionnaire (SF-MPQ). A score \>=3 is considered as moderate pain.
PrimaryUsage of epidural infusion of local and opioid analgesics (ml)Within the first 5 postoperative days
PrimaryPersistent post surgical pain6 months following surgery
Pain is assessed by means of the Brief Pain Inventory (BPI-SF) and The McGill Pain Questionnaire (SF-MPQ). Persistent postoperative pain is measured both on a 11-point numeric pain rating scale and on a 10 cm visual analog scale (VAS). A score \>=3 is considered as moderate pain.
PrimaryPersistent post surgical pain12 months following surgery
Pain is assessed by means of the Brief Pain Inventory (BPI-SF) and The McGill Pain Questionnaire (SF-MPQ). Persistent postoperative pain is measured both on a 11-point numeric pain rating scale and on a 10 cm visual analog scale (VAS). A score \>=3 is considered as moderate pain.
PrimaryEarly postoperative pain14 days (+/-3 days) following discharge
Early postoperative pain is measured on day 14 (+/-3 days) following discharge pain using the Brief Pain Inventory (BPI-SF) and The McGill Pain Questionnaire (SF-MPQ). A score \>=3 is considered as moderate pain.
SecondaryConsumption of opioid analgesicsWithin the first 5 postoperative days
SecondaryTime to first request for additional analgesicsWithin the first 5 postoperative days
SecondaryAnalgesia related side-effectsWithin the first 5 postoperative days
Evaluation of the presence and/or severity of confusion, hallucinations, nausea, vomiting, usage of antiemetic drugs, urinary retention, sedation, pruitus, headache, respiratory depression, motor blockade and dizziness
SecondaryConvalescence of gastrointestinal functionWithin the first 5 postoperative daysConvalescence of gastrointestinal function (time to first defecation)
SecondaryHealth related quality of lifeDay 14 (+/-3 days) following dischargeHealth related quality of life is measured with the EORCT QLQ-C30 and EORCT QLQ-LC13 questionnaires.
SecondaryPatient satisfactionWithin the first 5 postoperative daysPatient satisfaction is assesed with the EORCT-INPATSAT32 questionnaire
SecondaryIntensity of preoperative anxiety2 hours after administration of the first dose of study medicationAnxiety is measured on a 11-point numeric rating scale (NRS).
SecondaryConvalescence of lung function (spirometry)Within the first five postoperative daysFVC, FEV-1 and PEF is measured.
SecondarySleep qualityWithin the first five postoperative daysSleep quality is measured on a 11-point numeric rating scale (NRS)
SecondaryWalking distance (meters)Postoperative day 3Ability to walk is measured by means of the 6-minutes walking test on postoperative day 3.
SecondaryFatigueWithin the first 5 postoperative daysFatigue is measured on a 4-point verbal rating scale (0=None, 1=Mild, 2=Moderate, 3=Severe).
SecondaryHospital length of stay (days)At time of discharge
SecondaryHealth related quality of life3 months following surgeryHealth related quality of life is measured with the EORCT QLQ-C30 and EORCT QLQ-LC13 questionnaires.
SecondaryHealth related quality of life6 months following surgeryHealth related quality of life is measured with the EORCT QLQ-C30 and EORCT QLQ-LC13 questionnaires.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01116583/registered